key: cord-0312526-ye5b2fce
authors: Maher, M. C.; Soriaga, L. B.; Gupta, A.; di Iulio, J.; Ledoux, S.; Smithey, M. J.; Cathcart, A. L.; McKusick, K.; Sun, D.; Aldinger, M.; Alexander, E.; Purcell, L.; Ding, X.; Peppercorn, A. F.; Austin, D. J.; Mogalian, E.; Yeh, W. W.; Shapiro, A. E.; Corti, D.; Virgin, H. W.; Pang, P. S.; Telenti, A.
title: Antibody therapy reverses biological signatures of COVID-19 progression
date: 2021-12-27
journal: nan
DOI: 10.1101/2021.12.21.21268197
sha: bcffea3cbee55566cbd35094a141e6c9e4db55e9
doc_id: 312526
cord_uid: ye5b2fce

Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of SARS-CoV-2 infection. Several laboratory parameters identified study participants at greater risk of severe disease, including a high neutrophil-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test and whole blood transcriptome profiles. Sotrovimab treatment in these groups was associated with normalization of NLR and the transcriptomic profile, and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provided the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identified a 10-gene signature with similar predictive accuracy. In summary, we identified markers of risk for disease progression and demonstrated that normalization of these parameters occurs with antibody treatment of established infection.

Sotrovimab is a human monoclonal antibody (mAb) derived from an antibody isolated from a person recovered from SARS-CoV infection. This mAb broadly neutralizes SARS-CoV-2, SARS-CoV and other related animal sarbecoviruses [1] [2] [3] . Sotrovimab targets a highly conserved epitope in the SARS-CoV-2 Spike protein located in a site outside the receptor-binding motif (RBM), thus retaining in vitro activity against current SARS-CoV-2 variants of concern (VOC) (Alpha, Beta, Gamma, Delta, Omicron) and variants of interest (VOI) 4, 5 . The majority of mAbs developed for COVID-19 bind to the RBM, which engages the angiotensin-converting enzyme 2 (ACE2) receptor. The RBM is one of the most mutable and immunogenic regions of the virus 6 . As a result, RBM antibodies as single agents and even when used in combination have not retained activity against some VOC/VOI 7-10 , particularly against Omicron VOC 5, 11, 12 .

Sotrovimab was recently tested in a multicenter, double-blind, phase 3 clinical trial (COMET-ICE, ClinicalTrials.gov NCT04545060) that recruited non-hospitalized participants with symptomatic COVID-19, and at least one known risk factor (age and/or comorbidities) for severe disease progression. Participants were randomized to a single intravenous infusion of sotrovimab 500 mg or placebo. In the interim analysis of the trial, sotrovimab significantly reduced the risk of all-cause hospitalization (>24 hours) or death from COVID-19 1 . The final data, now presented in preprint 2 , shows that among 1057 participants randomized (sotrovimab, 528; placebo, 529), all-cause hospitalization longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%] ) by 79% (95% CI, 50% to 91%; p<0.001).

While the impact of sotrovimab was profound, the relatively low rate of hospitalization or death amongst participants considered at risk for poor disease outcomes in the placebo arm led us to investigate if additional biomarkers or biomarker profiles beyond the known demographic and comorbid conditions could be identified. The setting of a randomized, controlled clinical trial presented a unique opportunity to identify signals of disease progression that resolved in response to treatment and could thus be used both to provide insights into COVID-19 pathogenesis, and as potential surrogate endpoints in the design of future trials. Thus, the present study aimed at identifying baseline correlates of hospitalization and severe disease/death in an at-risk population based on routine laboratory parameters, SARS-CoV-2 serology and on transcriptome analysis. It then sought to assess the impact of antibody treatment on these parameters. This approach enabled assessment of the impact of antibody treatment on populations with different intrinsic risks of disease progression, and the identification and testing of surrogates of treatment response.

clinical laboratory values. COMET-ICE 2 included 1057 adults with a positive local polymerase-chain-reaction or antigen SARS-CoV-2 test result and onset of symptoms within the prior 5 days ( Table 1) . We analyzed 63 available central laboratory parameters for their association to hospitalization or death (Suppl. File 1). On Day 1, pre-dose, white blood cell proportions were most predictive of eventual hospitalization or death ( Table 2) .

White blood cell proportions were also quantified by the neutrophil to lymphocyte ratio (NLR; area under a receiver operating characteristic curve, AUC=0.81). We found that an NLR greater or equal 6 provided an optimal cutoff for the highest enrichment for disease progression and is hereafter defined as 'high NLR' (Suppl. Fig. S1 ). Of the 36 hospitalizations or deaths that occurred in the COMET-ICE study, 29 of these were observed among the 903 participants with available NLR at Day 1, the day of dosing. NLR had a sensitivity of 45% [28%-63%] and a specificity of 95% [93%-96%] for the prediction of all-cause hospitalization or death (Fisher's exact p<0.001). NLR normalized more rapidly in participants receiving sotrovimab (Figure 1 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

Having SARS-CoV-2 anti-nucleocapsid antibodies provides protection against SARS-CoV-2 re-infection 13 . There is more limited information, however, on how serostatus may associate with severity of disease during acute infection. In the current study, seropositivity at baseline may indicate prior infection by SARS-CoV-2 or that a participant is already seroconverting during an acute infection episode. Seropositivity rates varied significantly by race/ethnicity, Table 3 . Seropositivity was also associated with lower viral RNA in nasopharyngeal swabs at baseline: mean 4.2 vs 6.4 log10 viral RNA in seropositive versus seronegative participants (Mann-Whitney U p=1e-36); Table 3 . Of the participants who received placebo and the serology results were available, 4/97 (4%) of seropositive participants progressed to hospitalization and/or death compared with 25/375 (7%) of the seronegative who progressed to hospitalization and/or death before Day 29. In participants who received placebo, there were no deaths or ICU admissions in those who were seropositive at baseline compared to 4 deaths (2 deaths before Day 29 and 2 additional deaths that occurred after Day 29) and 9 ICU admissions (2.4%) in those who were seronegative at baseline.

Of the 202 seropositive participants at baseline, 6 (3%) were hospitalized or died: 4/96 (4.2%) received placebo and 2/106 (1.9%) received sotrovimab. Notably, as the COMET-ICE study captured all-cause hospitalizations or death, all 4 seropositive participants in the placebo arm were hospitalized with COVID-19 diagnoses, while the two seropositive participants in the sotrovimab arm were hospitalized with events potentially unrelated to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint COVID-19 (one instance of diabetic foot, and one instance of non-small cell lung cancer).

No sotrovimab-treated participants died or were admitted to the ICU.

Identification of high-risk cluster using transcriptomics. We used whole blood transcriptomics to define additional laboratory-based predictors of disease progression and response to treatment. In theory, such transcriptome signatures could provide complementary insight into the biology of risk and recovery. The sub-study included samples collected prior to treatment on Day 1 and at Day 8 from 303 patients. Among these 303 patients, 6/152 (3.9%) participants were hospitalized in the placebo group and 2/151 (1.3%) participants were hospitalized in the sotrovimab group.

We visualized the transcriptomes of each patient using Uniform Manifold Approximation and Projection (UMAP). We noted that from Day 1 to Day 8, the distribution of all transcriptome profiles tended to shift towards higher values of UMAP component 2 ( Figure 2a) . We defined a putative risk cluster based on the differences in the distributions of Day 1 and Day 8 samples in the UMAP (see Methods). The described risk cluster includes Day 1 and Day 8 transcriptomics profiles for 6 of 8 hospitalized participants (Figure 2b) . Participants in the high-risk cluster were significantly older, white, with a higher NLR, and higher viral RNA levels in nasopharyngeal samples (Suppl. Table S1 ).

The cluster analysis also highlighted that baseline seropositive participants were less likely to be associated with the high-risk transcriptome cluster on Day 1 and no seropositive patient remained in the high-risk cluster by Day 8 (Figure 2c) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The two hospitalized participants mis-identified by the baseline transcriptome analysis were in the sotrovimab arm. One of the two participants had undetectable viral RNA in nasopharyngeal swabs at enrollment, and through 8 days post-enrollment when blood was drawn for the transcriptome analysis. This patient was then hospitalized by Day 21 with elevated viral load, suggestive of a unique clinical course. The second misidentified patient treated with sotrovimab was hospitalized due to a small intestinal obstruction deemed unrelated to COVID-19. Therefore, we found support for the hypothesis that the area outlined in red in is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint sotrovimab was also associated with a more rapid decline in viral RNA in nasopharyngeal samples by Day 8 (Figure 3 ).

Examining the biology of the transcriptome-defined high-risk cluster. For both Day 1 and Day 8 visits, we scored genes for differential expression between high versus lowrisk clusters. We found a widespread transcriptional shift with thousands of genes identified as differentially expressed after adjusting for multiple comparisons (Figure 4a , Suppl. File 2). We characterized differentially expressed genes via gene-set enrichment analysis using the MSigDB Hallmark Gene Set annotation 14 . The most enriched Hallmark Gene Sets were associated with innate immune responses, in particular the complement system set, inflammatory response set, as well as the interferon alpha and gamma response gene expression modules (Figure 4b) . Overexpression of genes in these pathways agrees well with previous work showing strong associations between increased innate immune system activation and disease severity 15 . In summary, whole transcriptome analysis is consistent with a significant inflammatory response and identifies participants on Day 1 that have a high risk of disease progression, a finding that is further supported by the lack of normalization of the high-risk transcriptome profile in participants who were subsequently hospitalized.

Having established a transcriptomic profile associated with risk of COVID-19 progression, recovery, and treatment response, we next determined whether a smaller number of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint mRNAs that might practically be measured by RT-PCR captured the predictive power of the overall transcriptome. Such an approach is preferable due to lower cost and greatly reduced turnaround time relative to whole transcriptome sequencing. To select a gene panel, we clustered genes into 10 groups according to their co-expression patterns across participants (Suppl. Fig. S2 ). This was accomplished using UMAP and K-means clustering. We then selected the top gene from each group as candidate for identification of a risk-predictive set of 10 genes. Table S2. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint

We defined clinical laboratory and molecular biomarkers that can potentially identify participants with mild to moderate COVID-19 who are at highest risk of progression to severe disease and hospitalization or death using data collected in the prospective, phase 3 pivotal study COMET-ICE. Baseline NLR and a 10-gene transcriptomic signature associated with all-cause hospitalization or death with respective sensitivity and specificity of 33% and 93% (NLR) and of 87% and 64% (10-gene panel) on the transcriptomics sub-cohort. Changes in these biomarkers were also associated with response to treatment with the monoclonal antibody sotrovimab.

Currently, the risk of developing severe COVID-19 has been associated with a number of demographic factors such as age and specific comorbidities. However, there is considerable heterogeneity in disease outcome that would benefit from additional stratification of risk. NLR, the simple ratio of neutrophil over lymphocyte counts could be informative and easy to implement, an observation supported by other studies [16] [17] [18] Though NLR sensitivity is low, the high specificity suggests that high NLR could be used as a triage test for persons at high risk of progressing and could prioritize those individuals for closer monitoring. Serostatus, defined here as IgG antibody response to nucleocapsid, is also a predictor of disease severity. None of the participants that were seropositive at baseline, whether because of previous infection or because of ongoing seroconversion 19 died or were admitted to the ICU. Seropositive participants had lower levels of viral RNA in nasopharyngeal samples and were less likely to present or maintain a risk transcriptome profile. One caveat of this analysis is that VOCs that have decreased . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint sensitivity to antibodies induced by vaccination (e.g., Delta and Omicron) were not circulating at the time of enrollment in the study. Therefore, additional analysis may be needed to confirm the protective effect of seropositivity in the current phase of the pandemic.

Whole blood transcriptome analysis revealed a signature of disease severity that encompassed overexpression of genes involved in interferon response, inflammation and the complement system. We showed that a full transcriptome signature can be captured faithfully with a 10-gene panel. Use of a simple expression signature lowers the bar for an eventual implementation, as recently shown by work to make a three gene tuberculosis signature using point-of-care rapid testing 20 .

An important effort of the present work was to define whether the set of predictive parameters of hospitalization and disease severity was also modified by treatment with sotrovimab; i.e., whether these parameters could serve as surrogate markers of sotrovimab response because they are modified by treatment and strongly associated to the study clinical endpoints of interest. Indeed, sotrovimab accelerated the normalization of NLR and the transcriptome profiles in a statistically significant manner. In particular, hospitalized participants in the placebo group retained the transcriptome profile associated with risk by Day 8 at a time when the majority of study participants normalized their peripheral blood gene expression profiles.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint One topic of debate in the field is the value of measuring the levels of viral RNA in nasopharyngeal samples. In the present study, viral RNA levels measured by RT-PCR were of modest value as a baseline predictor. However, there was an association between viral RNA levels and the predictors of risk that we explored: NLR, serology and transcriptome profiles. Participants at risk of severe disease and hospitalization present higher levels of baseline nasopharyngeal viral RNA 21 . Weinreich et al. 22 reported that mAb therapy had a significant effect on participants with a high viral load at baseline.

Chen et al. 23 reported a decreased viral load at day 11 did not appear to be a clinically meaningful end point, since the viral load was substantially reduced from baseline for the majority of patients, including those in the placebo group, a finding that is consistent with the natural course of the disease. Gottlieb et al. 24 reported that treatment with mAb combination therapy, but not monotherapy, resulted in a reduction in SARS-CoV-2 log viral load at day 11 in participants with mild to moderate COVID-19. In the present work, resolution of disease was associated with decrease of viral load, in particular for participants receiving sotrovimab. However, taken together, these data indicate that viral load decline in upper airways is not a strong surrogate for clinical efficacy.

The strengths of the current study reside on the well-characterized, geographically diverse prospective pivotal clinical trial participant cohort with whole blood/RNA collected at multiple time points to evaluate response to treatment and disease characteristics over time. This dataset enabled the implementation of machine learning methods for predicting disease severity from both clinical and transcriptomic markers. A limitation of the study is that it included a pre-defined 'risk population" of adults based on demographic and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint comorbid factors. A second limitation is the low number of study endpoints in the transcriptomic sub-study. However, if validated in additional studies, this approach could expand the definition of risk to include participants that might otherwise not be considered for treatment based on risk criteria currently in use 25 . In conclusion, this study identifies laboratory parameters associated with COVID-19 disease progression and hospitalization and shows that sotrovimab treatment effectively contributes to normalization of these parameters.

Characteristics of clinical trial population. COMET-ICE 2 included 1057 adults with a positive local polymerase-chain-reaction or antigen SARS-CoV-2 test result and onset of symptoms within the prior 5 days ( Table 1) . Recruitment was between August 2020 and March 2021. Screening occurred within 24 hours prior to drug administration. Participants were required to be at risk for COVID-19 progression based on previously identified clinical parameters: age ≥55 years or adults with at least one of the following comorbid conditions: diabetes requiring medication, obesity (body-mass index >30 kg/m 2 ), chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m2), congestive heart failure (New York Heart Association class II or higher), chronic obstructive pulmonary disease, or moderate to severe asthma. Participants with already severe COVID-19, defined by shortness of breath at rest, oxygen saturation less than 94%, or requiring supplemental oxygen, were excluded. Participants were randomized 1:1 to receive either a single 500-mg infusion of sotrovimab or equal volume saline placebo. A subset of participants (n=303) consented for peripheral whole blood transcriptome . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint analysis. Participants who opted-in to the transcriptome sub-study had similar demographic, clinical and laboratory characteristics to those in the overall study. They were evenly divided between placebo and sotrovimab arms ( Table 1) oligonucleotides are used to select poly-adenylated RNAs from the total RNA after globin . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint mRNA reduction which are then fragmented and converted to cDNA using random primers in two steps to maintain strand specific information. Libraries were sequenced on Illumina NovaSeq 6000 (multiple sequencing runs, multiple instruments) to a target sequencing depth of 25 million paired-end reads per sample at a minimum read length of 50 bp. Samples were automatically selected by Q2 Solutions for repeat library preparation and sequencing based on pre-defined quality control metrics for ribosomal RNA fraction (>10% rRNA aligned reads threshold for repeat).

RNA-seq analysis. 701 sequenced libraries from 638 whole blood samples were delivered from Q2 solutions by processing batch and sequencing run. Reads were cropped to a common read length of 50 bp and low-quality bases and adapters were further trimmed using Trimmomatic (v. 0.39) 27 . Trimmed reads less than 31bp were discarded. Trimmed sequenced reads per library were then aligned to a custom reference genome using STAR (v 2.7.3a) 28 and to a custom reference transcriptome using Salmon Fig. S4) . For this baseline . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint To test the robustness of the embedding, this analysis was repeated for the full transcriptome (without PCA) for pathogen-associated transfer genes identified by di Iulio et al. 32 , and for immune-related pathway gene sets (Hallmark Gene Sets annotation). 14 In each case, a variety of nearest neighbor values were tried, and the embedding was run multiple times to ensure repeatability. In all cases, the embeddings were similar. For example, the observed gradient between Day 1 and Day 8 samples, as well as the relative placement of the hospitalized was always consistent.

High risk due to laboratory parameters vs low risk categorizations were derived as follows. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. S2) . From each cluster, we selected the gene most associated with risk according to its ANOVA F-score. Diversity-based selection using gene clustering significantly improved on greedy selection based on F-score alone (Suppl. Fig. S6a ) and yielded comparable performance to transfer-learned 32 and hallmark gene sets (Suppl. Fig. S6b) . To assess performance of this set of 10 genes representing co-expression clusters, we repeated this entire process within a five-fold cross-validation loop, including gene clustering. In this procedure the dataset is partitioned into five folds. For each of the five folds, we trained a model on the other four chunks to predict its values in an unbiased manner. To avoid overfitting due to patientspecific attributes, samples from the same patient on different days were always kept in the same fold.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; Figure 1 . Response to sotrovimab in high-risk group defined by neutrophil lymphocyte ratio (NLR). The time trend of NLR for sotrovimab versus placebo treated patients (hue) in the full cohort and low risk and high-risk groups as defined by NLR > 6. Error bars indicate the 95% confidence interval on the mean. Tables S1 and S2 Figures S1 to S6

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.21.21268197 doi: medRxiv preprint Supplemental Table S1 . Comparison of representative baseline values between high risk and low risk patients according to transcriptome data. Numbers in parentheses represent the percent of all patients in that category when denoted with "%"; otherwise, they represent the standard deviation. The numbers outside the parentheses are counts when represented with "%" in the parentheses. Otherwise, they are the mean value of that variable. P-value significance thresholds are based on a Bonferroni correction. Hospitalization or death 6 (5%) 2 (1%) 0.05 (N.S.)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ;

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes

SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study

The Molecular Signatures Database (MSigDB) hallmark gene set collection

COVID-19 and the human innate immune system

Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: A systematic review and meta-analysis

Neutrophil-tolymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis

Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial

Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results

Baseline SARS-CoV-2 Viral Load is Associated With COVID-19

Disease Severity and Clinical Outcomes: Post-Hoc Analyses of a Phase 2/3 Trial

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Individual and community-level risk for COVID-19 mortality in the United States

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

Trimmomatic: a flexible trimmer for Illumina sequence data

STAR: ultrafast universal RNA-seq aligner

Salmon provides fast and bias-aware quantification of transcript expression

RNA-Seq workflow: gene-level exploratory analysis and differential expression

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Transfer transcriptomic signatures for infectious diseases

Neutrophil Lymphocyte ratio cutoff 

High risk at day 8 18 4 Low risk at day 8 134 147

High risk at day 1 68 6Low risk at day 1 227 2Suppl. Fig. S5 .